title: Effects of nifedipine on rhythmic synchronous activity of human neocortical slices.
abstract: The antiepileptic effect of the dihydropyridine calcium channel blocker nifedipine was tested in neocortical slice preparations (n=27) from patients ranging in age from four to 46 years (mean=25) who underwent surgery for the treatment of intractable epilepsy. Epileptiform events consisted of spontaneously occurring rhythmic sharp waves as well as of untriggered epileptiform field potentials induced by omission of Mg(2+) from the superfusate, or epileptiform field potentials elicited by application of bicuculline and triggered by single electrical stimuli. (1) Spontaneous rhythmic sharp waves (n=6): with nifedipine (40micromol/l), the repetition rate was decreased down to 30% of initial value, whereas the area under the field potential remained nearly unchanged. (2) Untriggered low Mg(2+) epileptiform field potentials (n=6): with nifedipine (40micromol/l) the area under the field potentials was reduced while the action on the repetition rate was ambiguous. (3) Triggered bicuculline epileptiform field potentials (n=15): with nifedipine (40micromol/l; n=4), no antiepileptic effect was found. There was, however, a marked increase in the area under the epileptiform field potentials. The area under the field potentials was reduced only at a dosage of 60micromol/l (n=11). This effect was stronger when nifedipine was applied with a K(+) concentration raised from 4 to 8mmol/l. The results show that the calcium channel blocker nifedipine is able to reduce differential epileptiform discharges in human neocortical tissue. These observations are in line with previous findings, suggesting that calcium flux into neurons is involved in epileptogenesis. The present results therefore support the idea that some organic calcium antagonists may be useful in human epilepsy therapy, although the etiology of epileptic seizures seems to be a critical factor for the efficacy of the drug.
authors.affiliation: Institut für Physiologie, Universität Münster, Robert-Koch-Strasse 27a, 48149, Münster, Germany. straub@uni-muenster.de
authors.forename: H
authors.initials: H
authors.lastname: Straub
authors.forename: J M
authors.initials: JM
authors.lastname: Höhling
authors.forename: R
authors.initials: R
authors.lastname: Köhling
authors.forename: A
authors.initials: A
authors.lastname: Lücke
authors.forename: I
authors.initials: I
authors.lastname: Tuxhorn
authors.forename: A
authors.initials: A
authors.lastname: Ebner
authors.forename: P
authors.initials: P
authors.lastname: Wolf
authors.forename: H
authors.initials: H
authors.lastname: Pannek
authors.forename: F
authors.initials: F
authors.lastname: Oppel
authors.forename: E J
authors.initials: EJ
authors.lastname: Speckmann
mesh_terms: D000293:Adolescent; D001640:Bicuculline; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D003292:Convulsants; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D004827:Epilepsy / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D007231:Infant, Newborn; D008274:Magnesium / Q000008:administration & dosage; D019579:Neocortex / Q000502:physiology*; D009543:Nifedipine / Q000494:pharmacology*; D010507:Periodicity
chemical_list: D002121:Calcium Channel Blockers; D003292:Convulsants; D008274:Magnesium; D009543:Nifedipine; D001640:Bicuculline